2024 Archives

MRI in Localized and Recurrent Prostate Cancer

Baris Turkbey, MD | Nov 2024

In this 9-minute presentation, Baris Turkbey, MD, discusses the role of MRI in diagnosing localized and recurrent prostate cancer. He begins with a clinical case illustrating how MRI-guided biopsy can identify significant cancers missed by traditional systematic approaches.

Dr. Turkbey highlights the importance of standardized imaging practices, such as PI-RADS guidelines, which improve consistency in image acquisition and interpretation. He emphasizes that effective use of MRI involves coordination among radiologists, urologists, and pathologists, making quality control critical across all stages.

In recurrent prostate cancer, Dr. Turkbey stresses that MRI proves especially valuable in conjunction with PSMA PET imaging, aiding in localizing biochemical recurrence foci and enabling early curative interventions. He discusses updated PI-RR guidelines for interpreting MRI in post-treatment settings, recommending specific imaging sequences to improve detection in challenging scenarios. He demonstrates successful applications of MRI in detecting recurrence after surgery or radiotherapy, underscoring its diagnostic precision.

Genomics and Natural History of MRI Invisible vs Visible Cancers – Implications for Clinical Practice

Laurence Klotz, MD, FRCSC | Nov 2024

Laurence Klotz, MD, FRCSC, explores the genomics and natural history of MRI-visible versus invisible prostate cancers and their clinical implications.

In this 12-minute presentation, he highlights that while MRI is transformative in identifying significant prostate cancer, it misses about 15% of “invisible cancers.” Recent research reveals that the invisibility of these tumors correlates with favorable genomic profiles, including fewer genetic aberrations and reduced aggressivity.

Dr. Klotz presents compelling evidence linking visible tumors to adverse molecular features and worse clinical outcomes, whereas invisible cancers are largely indolent. He underscores the potential of radiogenomics in guiding treatment decisions, advocating for management strategies based on imaging rather than solely histology.

Dr. Klotz considers avoiding unnecessary systematic biopsies in favor of targeted MRI approaches can minimize patient anxiety and reduce overdiagnosis of insignificant cancers. However, challenges remain in addressing gray areas, such as PI-RADS 3 lesions and visible but low-grade cancers, which may require more nuanced management.

PCa Commentary | Volume 195 – November 2024

Edward Weber, MD | Nov 2024

The PATCH trial establishes transdermal estrogen as an effective alternative to Lupron for androgen deprivation. PASS confirms excellent long-term outcomes for active surveillance in Grade Group 1 disease. Emerging AI biopsy platforms improve Gleason grading precision and may enhance patient selection and monitoring for active surveillance.

Update on PRAISE-U Project – European Union Initiative in PC Screening

Monique Roobol, PhD, MSc | Nov 2024

Monique Roobol, PhD, focuses on prostate cancer screening practices in Europe, highlighting recent developments, ongoing initiatives, and future prospects. In 2022, the European Union (EU) updated its cancer screening recommendations, formally including prostate cancer alongside breast, lung, colorectal, and gastric cancers, spurring momentum for organized prostate cancer screening initiatives across Europe.

In this 11-minute presentation, Dr. Roobol shares the PRAISE-U initiative, launched following the EU’s recommendations. This initiative seeks to pilot and evaluate risk-based screening strategies across all EU member countries, including Spain, Ireland, Lithuania, and Poland.

Overview of Liquid Biomarkers

E. David Crawford, MD | Nov 2024

E. David Crawford, MD, professor of Urology at the University of California, San Diego, discusses advancements in risk stratification and biomarkers for prostate cancer detection. In his 10-minute presentation, he highlights the challenges of inconsistent screening guidelines, criticizing the current fragmented approach to PSA screening and underscoring the need for simplified, standardized messaging for primary care providers.

He advocates using a PSA cutoff of 1.5 ng/mL as a threshold for identifying at-risk individuals. Molecular markers, combined with PSA levels, improve precision in detecting clinically significant cancers and reducing overtreatment. Dr. Crawford outlines the complementary roles of PSA testing, molecular diagnostics, and multiparametric MRI in refining prostate cancer risk assessments.

Dr. Crawford introduces novel liquid biomarkers and their evolving role in guiding treatment decisions, cautioning that they serve as data points rather than definitive answers. Drawing analogies, he illustrates the multifactorial approach required for accurate prostate cancer diagnosis, akin to assessing risk in complex scenarios.